Global increases in kidney cancer incidence, 1973???1992, European Journal of Cancer Prevention, vol.11, issue.2, pp.171-178 ,
DOI : 10.1097/00008469-200204000-00010
Blood Pressure and Risk of Renal Cell Carcinoma in the European Prospective Investigation into Cancer and Nutrition, American Journal of Epidemiology, vol.167, issue.4, pp.438-446 ,
DOI : 10.1093/aje/kwm321
The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol, BJU International, vol.17, issue.2, pp.296-300, 2007. ,
DOI : 10.1111/j.1464-410X.2005.05771.x
Renal Cell Carcinoma Recurrence After Nephrectomy for Localized Disease: Predicting Survival From Time of Recurrence, Journal of Clinical Oncology, vol.24, issue.19, pp.3101-3107, 2006. ,
DOI : 10.1200/JCO.2005.04.8280
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.373, issue.19, pp.1814-1837, 2015. ,
DOI : 10.1056/NEJMoa1510016
Renal cell carcinoma in relation to cigarette smoking: Meta-analysis of 24 studies, International Journal of Cancer, vol.128, issue.1, pp.101-108 ,
DOI : 10.1002/ijc.20618
Body Size and Renal Cell Cancer Incidence in a Large US Cohort Study, American Journal of Epidemiology, vol.168, pp.268-277 ,
DOI : 10.1093/aje/kwn122
Obesity, Hypertension, and the Risk of Kidney Cancer in Men, New England Journal of Medicine, vol.343, issue.18, pp.1305-1311 ,
DOI : 10.1056/NEJM200011023431804
Family history and risk of renal cell carcinoma: results from a casecontrol study and systematic meta-analysis. Cancer Epidemiol ,
Genotype-phenotype correlations in von Hippel-Lindau disease, Human Mutation, vol.8, issue.2, pp.143-149 ,
DOI : 10.1002/humu.20385
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs???Part A: Renal, Penile, and Testicular Tumours, European Urology, vol.70, issue.1 ,
DOI : 10.1016/j.eururo.2016.02.029
Human chromophobe cell renal carcinoma, Virchows Archiv B Cell Pathology Including Molecular Pathology, vol.308, issue.1, pp.207-224, 1985. ,
DOI : 10.1007/BF02890129
Papillary (Chromophil) Renal Cell Carcinoma: Histomorphologic Characteristics and Evaluation of Conventional Pathologic Prognostic Parameters in 62 Cases, The American Journal of Surgical Pathology, vol.21, issue.6, pp.621-635 ,
DOI : 10.1097/00000478-199706000-00001
The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma, Cancer Cell, vol.26, issue.3, pp.319-330 ,
DOI : 10.1016/j.ccr.2014.07.014
Chromophobe renal cell carcinoma with sarcomatoid changes: case report and review of literature, Cent. Eur. J. Urol, vol.67, pp.31-34 ,
COLLECTING DUCT RENAL CELL CARCINOMA:, The Journal of Urology ,
DOI : 10.1097/00005392-200201000-00018
Collecting duct carcinoma of kidney, Semin. Diagn. Pathol, vol.15, pp.54-67 ,
Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma, Journal of Clinical Oncology, vol.20, issue.1, pp.289-296, 2002. ,
DOI : 10.1200/JCO.2002.20.1.289
Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria, Cancer, vol.20, issue.16, pp.2999-3006 ,
DOI : 10.1002/cncr.28151
Population-based Assessment of Survival After Cytoreductive Nephrectomy Versus No Surgery in Patients With Metastatic Renal Cell Carcinoma, Urology, vol.73, issue.2, pp.342-348, 2009. ,
DOI : 10.1016/j.urology.2008.09.022
URL : https://hal.archives-ouvertes.fr/inserm-00353570
Resection of metastatic renal cell carcinoma., Journal of Clinical Oncology, vol.16, issue.6, pp.2261-2267, 1998. ,
DOI : 10.1200/JCO.1998.16.6.2261
Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer ,
DOI : 10.1100/tswurol.2007.60
URL : https://doaj.org/article/f4a17d4bca2b49938b89e98b509fbc40
Radiotherapy and supportive care Clinical Progress in Renal Cancer, Oxford: Informa UK Ltd, pp.191-201, 2007. ,
Radiotherapy for renal-cell carcinoma, The Lancet Oncology, vol.15, issue.4, pp.170-177, 2014. ,
DOI : 10.1016/S1470-2045(13)70569-2
A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma., Journal of Clinical Oncology, vol.10, issue.2, pp.275-81, 1992. ,
DOI : 10.1200/JCO.1992.10.2.275
Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma, New England Journal of Medicine, vol.338, issue.18, pp.1272-1280, 1998. ,
DOI : 10.1056/NEJM199804303381805
Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review, Cancer Treatment Reviews, vol.34, issue.3, pp.193-205 ,
DOI : 10.1016/j.ctrv.2007.12.001
Chemotherapy in metastatic renal cell carcinoma today? A systematic review, Anti-Cancer Drugs, vol.24, pp.535-554 ,
DOI : 10.1097/CAD.0b013e3283609ec1
Ras regulation of vascular endothelial growth factor and angiogenesis, Methods Enzymol, vol.333, pp.267-83, 2001. ,
DOI : 10.1016/S0076-6879(01)33062-8
The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer, Oncology Research and Treatment, vol.25, issue.6, pp.511-519, 2002. ,
DOI : 10.1159/000068621
Bcl-2 Targets the Protein Kinase Raf-1 to Mitochondria, Cell, vol.87, issue.4, pp.629-667, 1996. ,
DOI : 10.1016/S0092-8674(00)81383-5
Altered expression of transforming growth factor-alpha: an early event in renal cell carcinoma development ,
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders, Cancer Res, vol.57, pp.4593-4602, 1997. ,
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2 ,
DOI : 10.1016/j.ejca.2008.10.026
Prise en charge du cancer r??nal m??tastatique, Progr??s en Urologie, vol.18, issue.7, pp.298-308, 2008. ,
DOI : 10.1016/S1166-7087(08)74558-5
Recommandations en Onco-Urologie 2010 : Cancer du rein, Progr??s en Urologie, vol.20, issue.4, pp.319-358, 2010. ,
DOI : 10.1016/S1166-7087(10)70048-8
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma, Journal of Clinical Oncology, vol.17, issue.8, pp.2530-2570, 1999. ,
DOI : 10.1200/JCO.1999.17.8.2530
Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie, Annals of Oncology, vol.13, issue.9, pp.1460-1468, 2002. ,
DOI : 10.1093/annonc/mdf257
Analyse critique des classifications pronostiques du cancer du rein m??tastatique, Progr??s en Urologie, vol.19, issue.6, pp.383-391, 2009. ,
DOI : 10.1016/j.purol.2008.10.011
Sequential therapy in renal cell carcinoma, Cancer, vol.26, issue.suppl, pp.2321-2327, 2009. ,
DOI : 10.1002/cncr.24241
??valuation de la prise en charge du cancer du rein m??tastatique ?? l?????re des th??rapies cibl??es. ??tude clinique r??trospective sur six ans, Prog En Urol [Internet]. mars 2013, pp.184-94, 2016. ,
DOI : 10.1016/j.purol.2012.09.014
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients, Targeted Oncology, vol.116, issue.18, pp.203-209, 2013. ,
DOI : 10.1007/s11523-012-0252-7
Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor, Acta Oncologica, vol.15, issue.3, pp.329-340, 2016. ,
DOI : 10.1111/j.1464-410X.2011.10186.x
Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma, Journal of Clinical Oncology, vol.32, issue.25, pp.2765-72, 2014. ,
DOI : 10.1200/JCO.2013.54.6911
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial, The Lancet, vol.378, issue.9807, pp.1931-1939, 2011. ,
DOI : 10.1016/S0140-6736(11)61613-9
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, The Lancet, vol.372, issue.9637, pp.449-56, 2008. ,
DOI : 10.1016/S0140-6736(08)61039-9
Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4), Annals of Oncology, vol.27, issue.3 ,
DOI : 10.1093/annonc/mdv612
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial, The Lancet Oncology, vol.15, issue.3, pp.286-296, 2014. ,
DOI : 10.1016/S1470-2045(14)70030-0
Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal Cell Carcinoma, European Urology, vol.58, issue.6, pp.906-917, 2010. ,
DOI : 10.1016/j.eururo.2010.09.008
Overview and management of toxicities associated with systemic therapies for advanced renal cell carcinoma, Urologic Oncology: Seminars and Original Investigations, vol.33, issue.12, pp.517-527, 2015. ,
DOI : 10.1016/j.urolonc.2015.07.020
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC), 2014. ,